SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $813,224,117 |
| Positions | 19 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| JOHNSON & JOHNSON | JNJ | COM | $107,923,282 | 424,945 |
| VERTEX PHARMACEUTICALS INC | VRTX | COM | $100,235,643 | 201,791 |
| ELI LILLY & CO | LLY | COM | $91,794,777 | 76,532 |
| ASCENDIS PHARMA A/S | ASND | ORD SHS | $69,011,133 | 258,740 |
| DEXCOM INC | DXCM | COM | $55,259,261 | 820,479 |
| AXSOME THERAPEUTICS INC. | AXSM | COM | $53,680,019 | 219,308 |
| JAZZ PHARMACEUTICALS PLC | JAZZ | SHS USD | $53,427,868 | 221,720 |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $43,985,837 | 866,716 |
| ARGENX SE | ARGX | SPONSORED ADR | $38,591,521 | 41,596 |
| MADRIGAL PHARMACEUTICALS INC | MDGL | COM | $36,659,187 | 68,273 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.